{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:00Z","timestamp":1787008680003,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 DK101856"],"award-info":[{"award-number":["R01 DK101856"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>No approved medication exists for the treatment of eosinophilic esophagitis (EoE) in the United States, which forces patients to utilize off-label drugs and\/or create their own formulations. We assessed the efficacy of a standardized compounded fluticasone suspension. To do this, we performed a retrospective cohort study identifying all EoE patients treated with compounded fluticasone. Compounded fluticasone was prescribed during routine clinical care and dispensed by a specialty compounding pharmacy. Clinical data were extracted from medical records. Outcomes (symptomatic, endoscopic, and histologic) were assessed after the initial and last compounded fluticasone treatment in our system. There were 27 included patients (mean age 34.2; 67% male; 96% white) treated for a mean length of 5.4\u2009\u00b1\u20094.4\u00a0months. The majority (89%) previously utilized dietary elimination or topical corticosteroids, and many (75%) had primary non-response or secondary loss of response to these treatments. After starting compounded fluticasone, symptoms and endoscopic findings improved [dysphagia (89 vs. 56%, P\u2009=\u20090.005), food impaction (59 vs. 4%, P\u2009=\u20090.003), heartburn (26 vs. 4%, P\u2009=\u20090.01), chest pain (26 vs. 8%, P\u2009=\u20090.05), white plaques (63 vs. 32%; P\u2009=\u20090.005), furrows (81 vs. 60%; P\u2009=\u20090.06), and edema (15 vs. 4%; P\u2009=\u20090.16)]. The median of the peak eosinophil counts decreased from 52 to 37 eos\/hpf (P\u2009=\u20090.10) and 35% of patients achieved &amp;lt;15 eos\/hpf. In conclusion, compounded fluticasone provided a significant improvement in symptoms and endoscopic findings, with more than a third achieving histologic response in a treatment refractory EoE population. Compounded fluticasone should be considered as an EoE management option.<\/jats:p>","DOI":"10.1093\/dote\/doaa120","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T02:40:02Z","timestamp":1607740802000},"source":"Crossref","is-referenced-by-count":16,"title":["Treatment with compounded fluticasone suspension improves the clinical, endoscopic, and histologic features of eosinophilic esophagitis"],"prefix":"10.1093","volume":"34","author":[{"given":"Corey J","family":"Ketchem","sequence":"first","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C","family":"Reed","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Stefanadis","sequence":"additional","affiliation":[{"name":"Chapel Hill Compounding Pharmacy, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1167-1101","authenticated-orcid":false,"given":"Evan S","family":"Dellon","sequence":"additional","affiliation":[{"name":"Center for Esophageal Diseases and Swallowing, and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"2021071306114429600_ref1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/j.gastro.2017.05.066","article-title":"Diagnosis and treatment of eosinophilic esophagitis","volume":"154","author":"Straumann","year":"2018","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1053\/j.gastro.2007.08.017","article-title":"Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment","volume":"133","author":"Furuta","year":"2007","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/0016-5085(78)90710-2","article-title":"Eosinophilic esophagitis in a patient with vigorous achalasia","volume":"74","author":"Landres","year":"1978","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF01296781","article-title":"Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome","volume":"38","author":"Attwood","year":"1993","journal-title":"Dig Dis Sci"},{"key":"2021071306114429600_ref5","first-page":"1419","article-title":"Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings","volume":"124","author":"Straumann","year":"1994","journal-title":"Schweiz Med Wochenschr"},{"key":"2021071306114429600_ref6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and natural history of eosinophilic esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ajg.2014.316","article-title":"Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States","volume":"110","author":"Jensen","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2021071306114429600_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/doy015","article-title":"Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course","volume":"31","author":"Shaheen","year":"2018","journal-title":"Dis Esophagus"},{"key":"2021071306114429600_ref9","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref11","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1007\/s10620-017-4642-7","article-title":"Six-food elimination diet and topical steroids are effective for eosinophilic esophagitis: a meta-regression","volume":"62","author":"Cotton","year":"2017","journal-title":"Dig Dis Sci"},{"key":"2021071306114429600_ref12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cgh.2017.03.016","article-title":"Drug development for eosinophilic esophagitis","volume":"15","author":"Hirano","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021071306114429600_ref13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref15","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.17554\/j.issn.2224-3992.2018.07.750","article-title":"Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis","volume":"7","author":"Reed","year":"2018","journal-title":"HSOA J Gastroenterol Hepatol Res"},{"key":"2021071306114429600_ref16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.cgh.2009.08.030","article-title":"Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease","volume":"7","author":"Dellon","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021071306114429600_ref17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/apt.14290","article-title":"Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis","volume":"46","author":"Reed","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2021071306114429600_ref18","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1038\/ctg.2017.27","article-title":"Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis","volume":"8","author":"Eluri","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2021071306114429600_ref19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/MCG.0000000000000718","article-title":"Causes and outcomes of Esophageal perforation in eosinophilic esophagitis","volume":"51","author":"Runge","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2021071306114429600_ref20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2011.02.040","article-title":"Eosinophilic esophagitis: updated consensus recommendations for children and adults","volume":"128","author":"Liacouras","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2021071306114429600_ref21","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.17554\/j.issn.2224-3992.2015.04.562","article-title":"Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis","volume":"4","author":"Wolf","year":"2015","journal-title":"J Gastroenterol Hepatol Res"},{"key":"2021071306114429600_ref22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cgh.2017.09.046","article-title":"Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study","volume":"16","author":"Reed","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021071306114429600_ref23","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1053\/j.gastro.2020.02.039","article-title":"Technical review on the Management of Eosinophilic Esophagitis: a report from the AGA Institute and the joint task force on allergy-immunology practice parameters","volume":"158","author":"Rank","year":"2020","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the Management of Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/doy098","article-title":"Oral delivery of fluticasone powder improves esophageal eosinophilic inflammation and symptoms in adults with eosinophilic esophagitis","volume":"31","author":"Kia","year":"2018","journal-title":"Dis Esophagus"},{"key":"2021071306114429600_ref26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12016-018-8697-9","article-title":"The role of the environment in eosinophilic esophagitis","volume":"57","author":"Dowling","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021071306114429600_ref27","first-page":"716","article-title":"Histopathologic variability in children with eosinophilic esophagitis","volume":"104","author":"Shah","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2021071306114429600_ref28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.gie.2006.04.037","article-title":"Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis","volume":"64","author":"Gonsalves","year":"2006","journal-title":"Gastrointest Endosc"},{"key":"2021071306114429600_ref29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"2021071306114429600_ref30","doi-asserted-by":"crossref","first-page":"S-16","DOI":"10.1016\/S0016-5085(14)60055-X","article-title":"Two new budesonide formulations are highly efficient for treatment of active eosinophilic esophagitis: results from a randomized, double-blind, double-dummy, placebo-controlled multicenter trial","volume":"146","author":"Miehlke","year":"2014","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref31","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/apt.15670","article-title":"Randomised clinical trial: the safety and tolerability of fluticasone propionate orally disintegrating tablets versus placebo for eosinophilic oesophagitis","volume":"51","author":"Hirano","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2021071306114429600_ref32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021071306114429600_ref33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ajg.2013.71","article-title":"ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE)","volume":"108","author":"Dellon","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2021071306114429600_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/dote\/doy049","article-title":"Systematic review and meta-regressions: management of eosinophilic esophagitis requires histologic assessment","volume":"31","author":"Chang","year":"2018","journal-title":"Dis Esophagus"},{"key":"2021071306114429600_ref35","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1053\/j.gastro.2013.08.015","article-title":"Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner","volume":"145","author":"Schoepfer","year":"2013","journal-title":"Gastroenterology"},{"key":"2021071306114429600_ref36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2005.05.004","article-title":"Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids","volume":"25","author":"Hubner","year":"2005","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021071306114429600_ref37","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1164\/ajrccm.162.6.9912072","article-title":"Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function","volume":"162","author":"Nielsen","year":"2000","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Diseases of the Esophagus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/dote\/article-pdf\/34\/7\/doaa120\/38917820\/doaa120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/dote\/article-pdf\/34\/7\/doaa120\/38917820\/doaa120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T02:14:01Z","timestamp":1626142441000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/dote\/article\/doi\/10.1093\/dote\/doaa120\/6031239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,12,12]]},"published-print":{"date-parts":[[2021,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/dote\/doaa120","relation":{},"ISSN":["1120-8694","1442-2050"],"issn-type":[{"value":"1120-8694","type":"print"},{"value":"1442-2050","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7]]},"published":{"date-parts":[[2020,12,12]]},"article-number":"doaa120"}}